With the rise of Transformers and Large Language Models (LLMs) in Chemistry and Biology, new avenues for the design and understanding of therapeutics have opened up to the scientific community. Protein sequences can be modeled as language and can take advantage of recent advances in LLMs, specifically with the abundance of our access to the protein sequence datasets. In this paper, we developed the GPCR-BERT model for understanding the sequential design of G Protein-Coupled Receptors (GPCRs). GPCRs are the target of over one-third of FDA-approved pharmaceuticals. However, there is a lack of comprehensive understanding regarding the relationship between amino acid sequence, ligand selectivity, and conformational motifs (such as NPxxY, CWxP, E/DRY). By utilizing the pre-trained protein model (Prot-Bert) and fine-tuning with prediction tasks of variations in the motifs, we were able to shed light on several relationships between residues in the binding pocket and some of the conserved motifs. To achieve this, we took advantage of attention weights, and hidden states of the model that are interpreted to extract the extent of contributions of amino acids in dictating the type of masked ones. The fine-tuned models demonstrated high accuracy in predicting hidden residues within the motifs. In addition, the analysis of embedding was performed over 3D structures to elucidate the higher-order interactions within the conformations of the receptors.

Recent advances in dynamic treatment regimes (DTRs) provide powerful optimal treatment searching algorithms, which are tailored to individuals' specific needs and able to maximize their expected clinical benefits. However, existing algorithms could suffer from insufficient sample size under optimal treatments, especially for chronic diseases involving long stages of decision-making. To address these challenges, we propose a novel individualized learning method which estimates the DTR with a focus on prioritizing alignment between the observed treatment trajectory and the one obtained by the optimal regime across decision stages. By relaxing the restriction that the observed trajectory must be fully aligned with the optimal treatments, our approach substantially improves the sample efficiency and stability of inverse probability weighted based methods. In particular, the proposed learning scheme builds a more general framework which includes the popular outcome weighted learning framework as a special case of ours. Moreover, we introduce the notion of stage importance scores along with an attention mechanism to explicitly account for heterogeneity among decision stages. We establish the theoretical properties of the proposed approach, including the Fisher consistency and finite-sample performance bound. Empirically, we evaluate the proposed method in extensive simulated environments and a real case study for COVID-19 pandemic.

Contrastive analysis (CA) refers to the exploration of variations uniquely enriched in a target dataset as compared to a corresponding background dataset generated from sources of variation that are irrelevant to a given task. For example, a biomedical data analyst may wish to find a small set of genes to use as a proxy for variations in genomic data only present among patients with a given disease (target) as opposed to healthy control subjects (background). However, as of yet the problem of feature selection in the CA setting has received little attention from the machine learning community. In this work we present contrastive feature selection (CFS), a method for performing feature selection in the CA setting. We motivate our approach with a novel information-theoretic analysis of representation learning in the CA setting, and we empirically validate CFS on a semi-synthetic dataset and four real-world biomedical datasets. We find that our method consistently outperforms previously proposed state-of-the-art supervised and fully unsupervised feature selection methods not designed for the CA setting. An open-source implementation of our method is available at https://github.com/suinleelab/CFS.

Recently, drug repurposing has emerged as an effective and resource-efficient paradigm for AD drug discovery. Among various methods for drug repurposing, network-based methods have shown promising results as they are capable of leveraging complex networks that integrate multiple interaction types, such as protein-protein interactions, to more effectively identify candidate drugs. However, existing approaches typically assume paths of the same length in the network have equal importance in identifying the therapeutic effect of drugs. Other domains have found that same length paths do not necessarily have the same importance. Thus, relying on this assumption may be deleterious to drug repurposing attempts. In this work, we propose MPI (Modeling Path Importance), a novel network-based method for AD drug repurposing. MPI is unique in that it prioritizes important paths via learned node embeddings, which can effectively capture a network's rich structural information. Thus, leveraging learned embeddings allows MPI to effectively differentiate the importance among paths. We evaluate MPI against a commonly used baseline method that identifies anti-AD drug candidates primarily based on the shortest paths between drugs and AD in the network. We observe that among the top-50 ranked drugs, MPI prioritizes 20.0% more drugs with anti-AD evidence compared to the baseline. Finally, Cox proportional-hazard models produced from insurance claims data aid us in identifying the use of etodolac, nicotine, and BBB-crossing ACE-INHs as having a reduced risk of AD, suggesting such drugs may be viable candidates for repurposing and should be explored further in future studies.

Due to cancer's complex nature and variable response to therapy, precision oncology informed by omics sequence analysis has become the current standard of care. However, the amount of data produced for each patients makes it difficult to quickly identify the best treatment regimen. Moreover, limited data availability has hindered computational methods' abilities to learn patterns associated with effective drug-cell line pairs. In this work, we propose the use of contrastive learning to improve learned drug and cell line representations by preserving relationship structures associated with drug mechanism of action and cell line cancer types. In addition to achieving enhanced performance relative to a state-of-the-art method, we find that classifiers using our learned representations exhibit a more balances reliance on drug- and cell line-derived features when making predictions. This facilitates more personalized drug prioritizations that are informed by signals related to drug resistance.

Building and analysing knowledge graphs (KGs) to aid drug discovery is a topical area of research. A salient feature of KGs is their ability to combine many heterogeneous data sources in a format that facilitates discovering connections. The utility of KGs has been exemplified in areas such as drug repurposing, with insights made through manual exploration and modelling of the data. In this article, we discuss promises and pitfalls of using natural language processing (NLP) to mine'unstructured text' - typically from scientific literature - as a data source for KGs. This draws on our experience of initially parsing'structured' data sources - such as ChEMBL - as the basis for data within a KG, and then enriching or expanding upon them using NLP. The fundamental promise of NLP for KGs is the automated extraction of data from millions of documents - a task practically impossible to do via human curation alone. However, there are many potential pitfalls in NLP-KG pipelines - such as incorrect named entity recognition and ontology linking - all of which could ultimately lead to erroneous inferences and conclusions.

Timely and accurate extraction of Adverse Drug Events (ADE) from biomedical literature is paramount for public safety, but involves slow and costly manual labor. We set out to improve drug safety monitoring (pharmacovigilance, PV) through the use of Natural Language Processing (NLP). We introduce BioDEX, a large-scale resource for Biomedical adverse Drug Event Extraction, rooted in the historical output of drug safety reporting in the U.S. BioDEX consists of 65k abstracts and 19k full-text biomedical papers with 256k associated document-level safety reports created by medical experts. The core features of these reports include the reported weight, age, and biological sex of a patient, a set of drugs taken by the patient, the drug dosages, the reactions experienced, and whether the reaction was life threatening. In this work, we consider the task of predicting the core information of the report given its originating paper. We estimate human performance to be 72.0% F1, whereas our best model achieves 62.3% F1, indicating significant headroom on this task. We also begin to explore ways in which these models could help professional PV reviewers. Our code and data are available: https://github.com/KarelDO/BioDEX.

Self-supervised learning has recently gained growing interest in molecular modeling for scientific tasks such as AI-assisted drug discovery. Current studies consider leveraging both 2D and 3D molecular structures for representation learning. However, relying on straightforward alignment strategies that treat each modality separately, these methods fail to exploit the intrinsic correlation between 2D and 3D representations that reflect the underlying structural characteristics of molecules, and only perform coarse-grained molecule-level alignment. To derive fine-grained alignment and promote structural molecule understanding, we introduce an atomic-relation level "blend-then-predict" self-supervised learning approach, MoleBLEND, which first blends atom relations represented by different modalities into one unified relation matrix for joint encoding, then recovers modality-specific information for 2D and 3D structures individually. By treating atom relationships as anchors, MoleBLEND organically aligns and integrates visually dissimilar 2D and 3D modalities of the same molecule at fine-grained atomic level, painting a more comprehensive depiction of each molecule. Extensive experiments show that MoleBLEND achieves state-of-the-art performance across major 2D/3D molecular benchmarks. We further provide theoretical insights from the perspective of mutual-information maximization, demonstrating that our method unifies contrastive, generative (cross-modality prediction) and mask-then-predict (single-modality prediction) objectives into one single cohesive framework.

The prevalent use of large language models (LLMs) in various domains has drawn attention to the issue of "hallucination," which refers to instances where LLMs generate factually inaccurate or ungrounded information. Existing techniques for hallucination detection in language assistants rely on intricate fuzzy, specific free-language-based chain of thought (CoT) techniques or parameter-based methods that suffer from interpretability issues. Additionally, the methods that identify hallucinations post-generation could not prevent their occurrence and suffer from inconsistent performance due to the influence of the instruction format and model style. In this paper, we introduce a novel pre-detection self-evaluation technique, referred to as SELF-FAMILIARITY, which focuses on evaluating the model's familiarity with the concepts present in the input instruction and withholding the generation of response in case of unfamiliar concepts. This approach emulates the human ability to refrain from responding to unfamiliar topics, thus reducing hallucinations. We validate SELF-FAMILIARITY across four different large language models, demonstrating consistently superior performance compared to existing techniques. Our findings propose a significant shift towards preemptive strategies for hallucination mitigation in LLM assistants, promising improvements in reliability, applicability, and interpretability.

When medical student Alyssa Murillo stepped into surgery, she was met with something most wouldn't expect to find in an operating room: a towering surgical robot. She wasn't there to observe the kind of surgeries she was used to seeing; instead she was getting an in-depth view inside the patient's body through the robot's video console. "It was incredible," says Murillo, who is now a forth-year general surgery resident at the University of California, San Francisco. "You have a full 3D view, which is different from any other minimally invasive surgery technique." The robot Murillo is referring to is the Da Vinci Surgical System.